Finch holds a well‑regarded intellectual property portfolio and platform in a cutting‑edge area of biotechnology, with legal validation of its patents and an asset base that is relatively clean and liquid in the short term. The balance sheet still shows positive equity and adequate near‑term liquidity, and the absence of complex goodwill or intangibles simplifies the financial picture.

The company has no revenue, persistent losses, heavy cash burn, and a high level of accumulated deficits, all while carrying meaningful leverage. R&D has effectively stopped, the operating business model has been dismantled, and the company is in a Chapter 11 process, creating high uncertainty around long‑term viability and residual value for stakeholders.

Looking ahead, Finch resembles a special‑situation IP monetization vehicle rather than a going‑concern biotech. The financials suggest limited runway unless the asset sale process generates sufficient proceeds to cover obligations and potentially return value. Outcomes will largely hinge on how attractive potential buyers find the microbiome IP portfolio and how effectively the company navigates the restructuring process, rather than on traditional growth or profitability drivers.